Overall Survival (OS) is another critical endpoint in clinical trials, referring to the length of time from either the diagnosis or the start of treatment that patients are still alive. While OS is the gold standard for assessing treatment efficacy, PFS offers earlier insights since it does not require the occurrence of death to measure. However, PFS can sometimes overestimate the benefits of a treatment if it delays progression without improving overall survival.
